Literature DB >> 1281622

Estimation of tumor growth fractions in archival formalin-fixed, paraffin-embedded tissues using two anti-PCNA/Cyclin monoclonal antibodies. Factors affecting reactivity.

A B Gelb1, O W Kamel, D P LeBrun, R A Warnke.   

Abstract

Immunohistochemical detection of cell cycle-related markers for estimation of tumor growth fractions using paraffin-embedded tissue sections would have applications in experimental and clinical pathology as an in situ histologic alternative to flow cytometry. The monoclonal antibodies 19A2 and PC10 detect the proliferating cell nuclear antigen (PCNA/Cyclin), an auxiliary protein to DNA polymerase-delta. In a prospective group of uniformly handled, formalin-fixed malignant lymphomas we previously demonstrated 19A2 to be a reliable marker of proliferative activity similar to Ki-67 in frozen tissue. The present study examines the applicability of this technique in archival formalin-fixed material. Studies on tonsilar tissue revealed that formalin fixation beyond 30 hours adversely affected reactivity of 19A2, possibly explaining the variable results in nonuniformly fixed archival material. We found that only 27 (56%) of 48 archival cases of infiltrating ductal carcinoma showed sufficient reactivity with 19A2 to permit reliable quantification of the tumor growth fraction. Acid pretreatment with 2N HCl had no apparent effect on 19A2 reactivity. Using both antibodies on a group of 32 archival lymphomas, carcinomas, and sarcomas, significantly more biopsies stained reliably for PC10 (84%) than for 19A2 (72%; P < 0.036). Further, none of the cases that did not react with PC10 reacted with 19A2. PC10 may recognize a different epitope of PCNA/Cyclin which may be more resistant to alterations by fixation. In the 23 cases that reliably stained for both markers, largely carcinomas, there was excellent correlation between estimated growth fractions (r = 0.96). Although immunostaining provides a useful way to estimate tumor growth fractions in paraffin-embedded tissues, modifications of technique and cautious interpretation of results are advisable when using archival material.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281622      PMCID: PMC1886764     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  19 in total

1.  Advantages of detecting monoclonal antibody binding to tissue sections with biotin and avidin reagents in Coplin jars.

Authors:  J M Bindl; R A Warnke
Journal:  Am J Clin Pathol       Date:  1986-04       Impact factor: 2.493

Review 2.  Driving the cell cycle: M phase kinase, its partners, and substrates.

Authors:  B Lewin
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

3.  Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase.

Authors:  J E Celis; A Celis
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

4.  An enhancement method for immunohistochemical staining of proliferating cell nuclear antigen in archival rodent tissues.

Authors:  A Greenwell; J F Foley; R R Maronpot
Journal:  Cancer Lett       Date:  1991-09       Impact factor: 8.679

5.  Regulation of proliferating cell nuclear antigen during the cell cycle.

Authors:  G F Morris; M B Mathews
Journal:  J Biol Chem       Date:  1989-08-15       Impact factor: 5.157

6.  Proliferative rates of non-Hodgkin's lymphomas as assessed by Ki-67 antibody.

Authors:  L M Weiss; J G Strickler; L J Medeiros; J Gerdes; H Stein; R A Warnke
Journal:  Hum Pathol       Date:  1987-11       Impact factor: 3.466

Review 7.  Cyclin (PCNA, auxiliary protein of DNA polymerase delta) is a central component of the pathway(s) leading to DNA replication and cell division.

Authors:  J E Celis; P Madsen; A Celis; H V Nielsen; B Gesser
Journal:  FEBS Lett       Date:  1987-08-10       Impact factor: 4.124

8.  Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.

Authors:  R Bravo; R Frank; P A Blundell; H Macdonald-Bravo
Journal:  Nature       Date:  1987 Apr 2-8       Impact factor: 49.962

9.  Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.

Authors:  P A Hall; D A Levison; A L Woods; C C Yu; D B Kellock; J A Watkins; D M Barnes; C E Gillett; R Camplejohn; R Dover
Journal:  J Pathol       Date:  1990-12       Impact factor: 7.996

10.  Existence of two populations of cyclin/proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites.

Authors:  R Bravo; H Macdonald-Bravo
Journal:  J Cell Biol       Date:  1987-10       Impact factor: 10.539

View more
  7 in total

1.  Chromatin-bound PCNA as S-phase marker in mononuclear blood cells of patients with acute lymphoblastic leukaemia or multiple myeloma.

Authors:  F Zölzer; O Basu; P U Devi; S P Mohanty; C Streffer
Journal:  Cell Prolif       Date:  2010-12       Impact factor: 6.831

2.  Recurrence of meningiomas versus proliferating cell nuclear antigen (PCNA) positivity and AgNOR counting.

Authors:  E Demirtaş; F Yilmaz; I Ovül; K Oner
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

3.  Impact of simultaneous assay, the PCNA, cyclinD1, and DNA content with specimens before and after preoperative radiotherapy on prognosis of esophageal cancer-possible incorporation into clinical TNM staging system.

Authors:  Shu-Chai Zhu; Ren Li; Yu-Xiang Wang; Wei Feng; Juan Li; Rong Qiu
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

Review 4.  Oral premalignant lesions: from the pathological viewpoint.

Authors:  Toshiyuki Izumo
Journal:  Int J Clin Oncol       Date:  2011-01-14       Impact factor: 3.402

5.  Apoptosis in human hepatocellular carcinoma and in liver cell dysplasia is correlated with p53 protein immunoreactivity.

Authors:  M Zhao; A Zimmermann
Journal:  J Clin Pathol       Date:  1997-05       Impact factor: 3.411

6.  Immunohistochemical analysis of p53 protein overexpression in liver cell dysplasia and in hepatocellular carcinoma.

Authors:  M Zhao; N X Zhang; J A Laissue; A Zimmermann
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

7.  Evaluation of proliferation parameters in in vivo bromodeoxyuridine labelled lung cancers.

Authors:  M M Tinnemans; M H Lenders; G P ten Velde; S S Wagenaar; G H Blijham; F C Ramaekers; B Schutte
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.